김안수

This profile gathers the share dealings of 김안수 in 에이프로젠바이오로직스, where the filings describe the role as chief executive. Between 24 May 2024 and 15 April 2026, the trades on record add up to 3 filings.

In open-market terms, that means 2 purchases on one side and 1 sale on the other. The totals do not cover 3 filings with an undisclosed amount. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. 2026 to date brings no purchases and 1 sale.

The newest entry dates from 8 May 2026: an open-market sale, in 에이프로젠바이오로직스. The clock since the last published purchase (28 June 2024) now reads 849 days. Filings reach the DART (FSS) feed a median of 7 days after the trade. The shorter that gap, the sooner other investors can see what insiders have done. These figures are compiled from regulatory filings published by DART (FSS). They describe what insiders did and are not a recommendation.